While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...
Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...
Opens in a new tab or window Use of GLP-1 receptor agonists for obesity was tied to a reduced risk of glaucoma versus other weight-loss drugs. The findings were in line with those of a previous ...
23hon MSN
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...
Increasing access to these effective evidence-based treatments would benefit our society as a whole, not just those impacted ...
As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.
Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback